Aaron Berger, MD, discusses how different formulations of abiraterone acetate can be selected based on patient compliance factors, particularly regarding fasting requirements, for treating both metastatic castration-resistant prostate cancer and high-risk localized prostate cancer cases.
Oliver Sartor, MD, discusses how 68galliumPSMA-11 PET-CT imaging is utilized in prostate cancer management, addressing its clinical applications, availability challenges, role in treatment eligibility assessment, unmet needs, and patient case considerations for metastatic castration-resistant prostate cancer (mCRPC).
Neal Shore, MD, FACS discusses how a 65-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) underwent a treatment journey that included androgen deprivation therapy, docetaxel, cabazitaxel, and enzalutamide before ultimately being evaluated for Lutetium-177 therapy based on PSMA PET imaging and trial data.
Scott T. Tagawa, MD, MS, FACP, FASCO, a medical oncologist specializing in urothelial carcinoma, reviews two patient cases and provides clinical insights on treatment decisions and ongoing research.
Paul M. Yonover, MD, FACS, reviews two cases of patients with prostate cancer and provides insights on imaging, biomarker testing, and treatment decision-making.
Stephen J. Freedland, MD, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and discusses the available treatment options and data that influence treatment selection for patients with the disease.
Karim Chamie, MD, presents 2 cases of patients with muscle-invasive bladder cancer (MIBC), reviews the chosen treatment regimens, and details which clinical and non-clinical factors influence treatment recommendations.
Dr Brian Helfand presents two cases of men with prostate cancer and discusses the role of positron emission tomography (PET)-based imaging in management of patients with the disease.
Neal Shore, MD, FACS, presents the case of a 74-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and discusses the factors that influence treatment selection for patients with the disease.
Jason Hafron, MD, presents the profile of a 66-year-old man with metastatic castration-sensitive prostate cancer, details the available treatment regimens, and discusses clinical trial data on the use of androgen deprivation therapy combined with a treatment-intensifying agent.
Gordon A. Brown, DO, presents the case of a man with prostate cancer, reviews available treatment options, and discusses data on combination androgen deprivation therapy/apalutamide in patients with metastatic castration-sensitive prostate cancer.
Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer, reviews the potential treatment options, including PARP inhibitors, and highlights the importance of genetic testing when selecting treatment regimens.
Judd W. Moul, MD, FACS, provides insight on screening and diagnosis of prostate cancer, and comments on the use of biomarker tests to aid in risk stratification, management, and treatment.
Karim Chamie, MD, reviews a high-risk muscle invasive bladder cancer case and highlights potential treatment options.
